Cite

    Kwon, J. et al. (2022). Continuous administration of mirabegron has advantages in inhibition of central sensitization compared with short‐term treatment cessation in a mouse model of overactive bladder. Neurourology and urodynamics. 41 (6), pp. 1355-1363. [Online].